This article is more than 5 years old. Information may no longer be current.

Investigational DPP-IV inhibitor at various doses reduced HbA1c in type 2 diabetes

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 2b results have demonstrated that an investigational, once-weekly DPP-IV inhibitor significantly lowered HbA1c, compared with placebo, among patients with type 2 diabetes. The drug was also well-tolerated with a safety profile similar to that of placebo, according to a press release issued from the 48th European Association for the Study of Diabetes Annual Meeting in Berlin.

The drug, MK-3102 (Merck), was administered at five doses (0.25 mg, 1 mg, 3 mg, 10 mg and 25 mg) to patients with type 2 diabetes with inadequate glycemic control on diet and exercise.

Patients with a mean baseline HbA1c of 8% (n=685) were randomly assigned to MK-3102 at one of five once-weekly doses (0.25 mg, n=113; 1 mg, n=115; 3 mg, n=114; 10 mg, n=115; 25 mg, n=114) or placebo (n=114) for 12 weeks. According to the press release, the primary endpoint was change in HbA1c from baseline at the trial’s end across all doses. Secondary endpoints included 2-hour post-meal glucose and fasting plasma glucose (FPG).

Patients assigned to MK-3102 at all doses had a significantly lower HbA1c compared with those assigned to placebo (P<.001). At 12 weeks, placebo-adjusted reduction in HbA1c from baseline was 0.71% in the 25-mg group, 0.67% in the 10-mg group, 0.49% in the 3-mg group, 0.50% in the 1-mg group and 0.28% in the 0.25-mg group.

Among secondary endpoints, a statistically significant (P<.001) trend was observed across all doses for both 2-hour post-meal glucose and FPG. Placebo-adjusted reductions in HbA1c from baseline to 12 weeks for 2-hour post-meal glucose were 2.5 mmol/L for 25 mg; 2.3 mmol/L for 10 mg; 1.9 mmol/L for 3 mg; 1.9 mmol/L for 1 mg; and 1.0 mmol/L for 0.25 mg. Reductions for FPG were 1.2 mmol/L for 25 mg; 0.7 mmol/L for 10 mg; 0.8 mmol/L for 3 mg; 1.1 mmol/L for 1 mg; and 0.1 mmol/L for 0.25 mg.

According to the press release, the study drug was generally well-tolerated, with a safety profile similar to that of placebo.

For more information:

Gantz I. #110. Presented at: the European Association for the Study of Diabetes 48th Annual Meeting; October 1-5, 2012; Berlin.